CDK9 and hematopoietic and lymphoid system neoplasm: Indeed, implementation of CDK9 inhibition as a therapeutic strategy for cancer has been hampered by the poor selectivity and associated off target toxicity of CDK9 inhibitor drugs that have been clinically tested, predominantly in the context of blood cancer [15, 23, 29].